3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Venous Thromboembolism
1
TP53 Y220C Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Pulmonary Embolism
1
Prostatic Neoplasms, Castration-Resistant
1
Peripheral Nervous System Diseases
1
Neoplasms
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Healthy Participants
1
Healthy Adult Participants
1
Endometrial Neoplasms
1
Drug-drug Interaction,SHR3680
1
Cardiotoxicity
1
Breast Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Cyclophosphamide
8
fludarabine
5
Radiation
3
Doxorubicin
3
tazemetostat
2
pembrolizumab
2
Specimen Handling
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Leukapheresis
2
Injections
2
Ifosfamide
2
peposertib
1
pazopanib
1
olaparib
1
lutetium Lu 177 dotatate
1
liposomal doxorubicin
1
fludarabine phosphate
1
anlotinib
1
aldesleukin
1
Zoledronic Acid
1
X-Rays
1
Trabectedin
1
Tablets
1
Rosuvastatin Calcium
1
Quality of Life
1
Phantoms, Imaging
1
Nivolumab
1
Midazolam
1
Interleukin-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
Rosuvastatin Calcium
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled